Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 220

1.

Association Between Cytokines and Liver Histology in Children with Nonalcoholic Fatty Liver Disease.

Perito ER, Ajmera V, Bass NM, Rosenthal P, Lavine JE, Schwimmer JB, Yates KP, Diehl AM, Molleston JP, Murray KF, Scheimann A, Gill R, Glidden D, Aouizerat B.

Hepatol Commun. 2017 Sep;1(7):609-622. doi: 10.1002/hep4.1068. Epub 2017 Jul 17.

PMID:
29130075
2.

Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children.

Newton KP, Feldman HS, Chambers CD, Wilson L, Behling C, Clark JM, Molleston JP, Chalasani N, Sanyal AJ, Fishbein MH, Lavine JE, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN).

J Pediatr. 2017 Aug;187:141-146.e1. doi: 10.1016/j.jpeds.2017.03.007. Epub 2017 Mar 30.

PMID:
28366357
3.

Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.

Nelson JE, Handa P, Aouizerat B, Wilson L, Vemulakonda LA, Yeh MM, Kowdley KV; NASH Clinical Research Network.

Aliment Pharmacol Ther. 2016 Dec;44(11-12):1253-1264. doi: 10.1111/apt.13824. Epub 2016 Oct 11.

4.

Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.

Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, Gill R, Loomba R, Diehl AM, Aouizerat BE; NASH Clinical Research Network.

Hepatology. 2017 Jan;65(1):65-77. doi: 10.1002/hep.28776. Epub 2016 Oct 12.

5.

Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis.

Yang JD, Abdelmalek MF, Guy CD, Gill RM, Lavine JE, Yates K, Klair J, Terrault NA, Clark JM, Unalp-Arida A, Diehl AM, Suzuki A; Nonalcoholic Steatohepatitis Clinical Research Network.

Clin Gastroenterol Hepatol. 2017 Jan;15(1):127-131.e2. doi: 10.1016/j.cgh.2016.07.034. Epub 2016 Aug 12.

6.

Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary.

Bajaj JS, Frederick RT, Bass NM, Ghabril M, Coyne K, Margolis MK, Santoro M, Coakley DF, Mokhtarani M, Jurek M, Scharschmidt BF.

Metab Brain Dis. 2016 Oct;31(5):1081-93. doi: 10.1007/s11011-016-9851-9. Epub 2016 Jun 9.

PMID:
27278222
7.

Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease.

Corey KE, Vuppalanchi R, Vos M, Kohli R, Molleston JP, Wilson L, Unalp-Arida A, Cummings OW, Lavine JE, Chalasani N; Nonalcoholic Steatohepatitis Clinical Research Network.

J Pediatr Gastroenterol Nutr. 2015 Mar;60(3):360-7. doi: 10.1097/MPG.0000000000000584.

8.

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network.

Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7. Erratum in: Lancet. 2015 Mar 14;385(9972):946. Lancet. 2016 Apr 16;387(10028):1618.

9.

NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.

Corey KE, Vuppalanchi R, Wilson LA, Cummings OW, Chalasani N; NASH CRN.

Aliment Pharmacol Ther. 2015 Feb;41(3):301-9. doi: 10.1111/apt.13035. Epub 2014 Nov 28.

10.

Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.

Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP.

Clin Gastroenterol Hepatol. 2014 Aug;12(8):1390-7.e2. doi: 10.1016/j.cgh.2013.12.021. Epub 2013 Dec 21.

11.

Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis.

Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN).

Liver Int. 2014 Sep;34(8):1250-8. doi: 10.1111/liv.12379. Epub 2013 Nov 24.

12.

Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.

Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS Jr, Alexeeva O, Zupanets IA, Grinevich V, Baranovsky A, Dudar L, Fadieienko G, Kharchenko N, Klaryts'ka I, Morozov V, Grewal P, McCashland T, Reddy KG, Reddy KR, Syplyviy V, Bass NM, Dickinson K, Norris C, Coakley D, Mokhtarani M, Scharschmidt BF; HALT-HE Study Group.

Hepatology. 2014 Mar;59(3):1073-83. doi: 10.1002/hep.26611.

13.

Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.

Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J; Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN).

Aliment Pharmacol Ther. 2013 Jul;38(2):134-43. doi: 10.1111/apt.12352. Epub 2013 May 29.

14.

Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients.

Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B, Doo E, Kleiner DE, Behling C, Loomba R; NASH CRN.

Hepatology. 2013 Nov;58(5):1644-54. doi: 10.1002/hep.26465. Epub 2013 Oct 2.

15.

Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations.

Nelson JE, Brunt EM, Kowdley KV; Nonalcoholic Steatohepatitis Clinical Research Network.

Hepatology. 2012 Nov;56(5):1730-40. doi: 10.1002/hep.25856. Epub 2012 Sep 20.

16.

Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.

Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, Sanyal AJ, Kowdley KV, Neuschwander-Tetri BA, Brunt EM, McCullough AJ, Bass NM, Diehl AM, Unalp-Arida A, Chalasani N; Nonalcoholic Steatohepatitis Clinical Research Network.

Hepatology. 2012 Oct;56(4):1311-8. doi: 10.1002/hep.25805. Epub 2012 Aug 21.

17.

Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis.

Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network.

Hepatology. 2012 Sep;56(3):943-51. doi: 10.1002/hep.25772. Epub 2012 Jul 26.

18.

Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease.

Guy CD, Suzuki A, Zdanowicz M, Abdelmalek MF, Burchette J, Unalp A, Diehl AM; NASH CRN.

Hepatology. 2012 Jun;55(6):1711-21. doi: 10.1002/hep.25559. Epub 2012 Apr 18.

19.

Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD.

Vos MB, Colvin R, Belt P, Molleston JP, Murray KF, Rosenthal P, Schwimmer JB, Tonascia J, Unalp A, Lavine JE; NASH CRN Research Group.

J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):90-6. doi: 10.1097/MPG.0b013e318229da1a.

20.

Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease.

Guy CD, Suzuki A, Burchette JL, Brunt EM, Abdelmalek MF, Cardona D, McCall SJ, Ünalp A, Belt P, Ferrell LD, Diehl AM; Nonalcoholic Steatohepatitis Clinical Research Network.

Hum Pathol. 2012 Jun;43(6):790-800. doi: 10.1016/j.humpath.2011.07.007. Epub 2011 Oct 28.

Supplemental Content

Loading ...
Support Center